Loading
A marker of stem cells in the gut and of stem-like cells in tumours, used to aim drugs at the cells that regrow a cancer.
LGR5, leucine-rich repeat-containing G-protein-coupled receptor 5, is a Wnt target gene that marks intestinal stem cells and stem-like cells in tumours, the cells thought to regrow a cancer after treatment. In head and neck squamous cell carcinoma and colorectal cancer it is being used to aim drugs at those cells: petosemtamab binds LGR5 and uses that binding to degrade EGFR selectively in tumour cells, and LGR5-directed antibody-drug conjugates have also been explored. Readers meet the term on the petosemtamab drug page, in the LiGeR-HN1 trial and within the Wnt and beta-catenin pathway. It is also part of the wider story of cancer stem cells and phenotypic plasticity.
Shares LiGeR-HN1, Petosemtamab, Head and neck squamous cell carcinoma.
Shares LiGeR-HN1, Petosemtamab, Head and neck squamous cell carcinoma.
Shares Petosemtamab, Wnt / β-catenin, Colorectal cancer.
Shares Petosemtamab, Head and neck squamous cell carcinoma, Colorectal cancer.
Shares Petosemtamab, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.
Shares Wnt / β-catenin, Colorectal cancer.